Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Leading Change in Academic Pharmacy: Report of the 2018-2019 AACP Academic Affairs Committee.

Gregory DF, Boje KM, Carter RA, Daugherty KK, Hagemeier NE, Munger MA, Umland EM, Wagner JL.

Am J Pharm Educ. 2019 Dec;83(10):7661. doi: 10.5688/ajpe7661.

2.

Student perceptions of the impact and value of incorporation of reflective writing across a pharmacy curriculum.

King AE, Joseph AS, Umland EM.

Curr Pharm Teach Learn. 2017 Sep;9(5):770-778. doi: 10.1016/j.cptl.2017.05.010. Epub 2017 Jul 14.

PMID:
29233303
3.

An evaluation of the opportunities for collaborative practice occurring in and the impact of interprofessional education on advanced pharmacy practice experiences.

Umland EM, Valenzano J, Brown C, Giordano C.

Curr Pharm Teach Learn. 2017 May;9(3):491-497. doi: 10.1016/j.cptl.2017.01.004. Epub 2017 Feb 21.

PMID:
29233290
4.

A Systematic Review of Assessment Tools Measuring Interprofessional Education Outcomes Relevant to Pharmacy Education.

Shrader S, Farland MZ, Danielson J, Sicat B, Umland EM.

Am J Pharm Educ. 2017 Aug;81(6):119. doi: 10.5688/ajpe816119. Review.

5.

Bazedoxifene and Conjugated Equine Estrogen: A Combination Product for the Management of Vasomotor Symptoms and Osteoporosis Prevention Associated with Menopause.

Umland EM, Karel L, Santoro N.

Pharmacotherapy. 2016 May;36(5):548-61. doi: 10.1002/phar.1749. Epub 2016 May 11. Review.

PMID:
27027527
6.

Report of the 2014-2015 Academic Affairs Standing Committee: Addressing Affordability, Accessibility, and Accountability.

Franson KL, Buring SM, Davis PJ, Krueger KP, Umland EM, Woodward JM, Youmans SL, Plaza CM.

Am J Pharm Educ. 2015 Oct 25;79(8):S13. doi: 10.5688/ajpe798S13. No abstract available.

7.

An Interprofessional Education Panel on Development, Implementation, and Assessment Strategies.

Kahaleh AA, Danielson J, Franson KL, Nuffer WA, Umland EM.

Am J Pharm Educ. 2015 Aug 25;79(6):78. doi: 10.5688/ajpe79678.

8.

Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis.

Schultz TC, Valenzano JP, Verzella JL, Umland EM.

Womens Health (Lond). 2015 Nov;11(6):805-14. doi: 10.2217/whe.15.39. Epub 2015 Sep 7. Review.

PMID:
26344800
9.

Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine.

Umland EM, Falconieri L.

Int J Womens Health. 2012;4:305-19. doi: 10.2147/IJWH.S24614. Epub 2012 Jul 5.

11.

Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms.

Umland EM.

J Manag Care Pharm. 2008 Apr;14(3 Suppl):14-9. Review.

12.

Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.

King AE, Umland EM.

Pharmacotherapy. 2008 May;28(5):667-77. doi: 10.1592/phco.28.5.667. Review.

PMID:
18447663
13.

Outpatient management of anticoagulation therapy.

du Breuil AL, Umland EM.

Am Fam Physician. 2007 Apr 1;75(7):1031-42. Review.

14.

Risedronate: a new oral bisphosphonate.

Umland EM, Boyce EG.

Clin Ther. 2001 Sep;23(9):1409-21. Review.

PMID:
11589256
15.

Sildenafil citrate: a therapeutic update.

Boyce EG, Umland EM.

Clin Ther. 2001 Jan;23(1):2-23. Review.

PMID:
11219477
16.

Phytoestrogens as therapeutic alternatives to traditional hormone replacement in postmenopausal women.

Umland EM, Cauffield JS, Kirk JK, Thomason TE.

Pharmacotherapy. 2000 Aug;20(8):981-90. Review. No abstract available.

PMID:
10939560
17.

The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers.

Umland EM, Rinaldi C, Parks SM, Boyce EG.

Ann Pharmacother. 1999 Dec;33(12):1315-28. Review.

PMID:
10630832
18.

Cardiovascular effects of troglitazone.

Umland EM, Romanelli AM.

Ann Pharmacother. 1999 Feb;33(2):229-32. Review. No abstract available.

PMID:
10084419

Supplemental Content

Loading ...
Support Center